Viking Global Investors LP trimmed its stake in aTyr Pharma Inc (NASDAQ:LIFE) by 22.1% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 1,384,300 shares of the biotechnology company’s stock after selling 393,484 shares during the period. Viking Global Investors LP owned approximately 4.65% of aTyr Pharma worth $4,845,000 as of its most recent SEC filing.
Other institutional investors and hedge funds have also recently modified their holdings of the company. Deutsche Bank AG bought a new position in aTyr Pharma in the fourth quarter worth $199,000. Dimensional Fund Advisors LP boosted its position in aTyr Pharma by 44.1% in the third quarter. Dimensional Fund Advisors LP now owns 83,848 shares of the biotechnology company’s stock worth $423,000 after purchasing an additional 25,676 shares during the last quarter. Victory Capital Management Inc. purchased a new position in aTyr Pharma in the third quarter worth about $455,000. Artal Group S.A. purchased a new position in aTyr Pharma in the third quarter worth about $1,263,000. Finally, Renaissance Technologies LLC lifted its position in shares of aTyr Pharma by 143.2% during the 4th quarter. Renaissance Technologies LLC now owns 279,400 shares of the biotechnology company’s stock valued at $978,000 after buying an additional 164,500 shares in the last quarter. 58.65% of the stock is owned by institutional investors and hedge funds.
A number of research analysts have recently weighed in on the company. Zacks Investment Research cut aTyr Pharma from a “buy” rating to a “hold” rating in a research report on Wednesday, January 17th. ValuEngine downgraded aTyr Pharma from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Finally, JPMorgan Chase & Co. downgraded aTyr Pharma from a “neutral” rating to an “underweight” rating in a research note on Wednesday, February 14th. Two research analysts have rated the stock with a sell rating, two have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $4.56.
aTyr Pharma Company Profile
aTyr Pharma, Inc is a clinical-stage biotherapeutics company. The Company is engaged in the discovery and clinical development of medicines for patients suffering from severe, rare diseases using its Physiocrine biology, a discovered set of physiological modulators. The Company focuses on the development of Physiocrine-based therapeutics for the treatment of rare diseases, including facioscapulohumeral muscular dystrophy (FSHD) and limb-girdle muscular dystrophy (LGMD) 2B.
Receive News & Ratings for aTyr Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for aTyr Pharma and related companies with MarketBeat.com's FREE daily email newsletter.